Australia vs the World: Psychedelic Regulation Compared

Forty-three countries now have some form of formal research or regulatory activity touching classical psychedelics. I know that because I spent a Saturday afternoon in Perth cross-referencing policy databases instead of losing at chess, which is probably a sign I need better hobbies. But the number surprised me when I first added it up , and it keeps shifting.

Australia made international headlines in February 2023 when the Therapeutic Goods Administration (TGA) rescheduled psilocybin and MDMA, allowing Authorised Prescribers to prescribe them under certain conditions from 1 July 2023. That decision was globally unusual. Most jurisdictions are still running clinical trials or sitting on parliamentary inquiries. A few have moved further. Most haven't moved at all.

This piece is a regulatory map, not a recommendation. Where these substances sit legally, and what can actually happen under each framework, varies enormously , and getting that wrong has serious consequences.

What the Australian framework actually allows

Psilocybin remains a Schedule 9 Prohibited Substance under the Poisons Standard. That classification has not changed. What changed in 2023 is the addition of a very specific, narrow exception: an approved Authorised Prescriber , a psychiatrist who has received approval from the TGA; may prescribe psilocybin under Schedule 8 (Controlled Drug) scheduling for one specific indication. The prescriber must apply to the TGA, demonstrate appropriate clinical oversight, and the supply must go through an approved pharmacy.

Outside that pathway, possession, supply, or use of psilocybin is a criminal offence under state and territory law. This is not a grey area. The Special Access Scheme also provides a pathway for individual unapproved medicines in specific clinical circumstances, but this too requires TGA engagement, not self-initiation by a patient.

MDMA received a parallel Schedule 8 pathway specifically for PTSD. Both moves were preceded by years of lobbying, a formal TGA scheduling delegate review, and considerable debate within the psychiatric community about whether the evidence base was mature enough to justify the step.

I'll say plainly: anyone consuming these substances outside the Authorised Prescriber pathway, recreationally or otherwise, is committing a criminal offence in every Australian state and territory. There is no personal-use exemption.

The United States: decriminalisation ≠ legalisation

The US position is genuinely complicated, and a lot of online commentary conflates different layers of law. At the federal level, psilocybin remains a Schedule I substance under the Controlled Substances Act; no accepted medical use, high potential for abuse. Full stop. The DEA has not changed this.

What has changed is a patchwork of state and city-level activity. Oregon's Measure 109, passed in 2020, created a state-licenced "psilocybin services" framework for supervised administration, distinct from clinical prescribing. Colorado followed in 2022 with Proposition 122. Cities including Denver, Oakland, and Santa Cruz have passed decriminalisation measures that deprioritise enforcement for personal possession, but these do not legalise supply or use.

The FDA has granted "Breakthrough Therapy" designation to psilocybin for specific indications under trial conditions, meaning it can move through the research pipeline faster, not that it's approved. These are important distinctions. The US framework is fragmented, contested, and does not provide a clear consumer access model the way Australia's Authorised Prescriber pathway does, however narrow that pathway is.

The Netherlands, Jamaica, and unregulated models

The Netherlands sits in a different category entirely. Psilocybin (the isolated compound) is a List I controlled substance under Dutch law. But psilocybin-containing mushrooms in dried form are also controlled. What remains in a legal grey zone is the sale of "magic truffles"; the sclerotia of certain Psilocybe species, through licenced "smart shops." This is not a regulated therapeutic model. It is a commercial gap that persists because of a technicality in how mushrooms versus truffles were scheduled in 2008. I wouldn't describe it as a policy framework so much as an unresolved anomaly.

Jamaica has no specific law criminalising psilocybin mushrooms, which has made it a destination for retreat operations. There is no formal regulatory oversight of those retreats, no prescriber framework, no quality control. The legal permissiveness is real; the consumer protections are not.

Canada's Section 56 exemptions

Canada sits close to, but not quite at; the Australian model. Health Canada has used Section 56 exemptions under the Controlled Drugs and Substances Act to allow specific individuals (primarily patients in end-of-life contexts and some healthcare providers) to access psilocybin. These exemptions are granted case by case, are not a broad prescriber pathway, and remain tightly controlled. Canada also runs a Special Access Program with some parallels to Australia's Special Access Scheme.

The practical difference from Australia's post-2023 model: Canada's exemptions are more individualised and administratively intensive. Australia's Authorised Prescriber model at least provides a replicable pathway, if psychiatrists are willing to apply and if TGA approvals are granted, which remains a constraint on uptake.

Switzerland and the broader European picture

Switzerland allows compassionate use applications for psilocybin through its health authority (Swissmedic), and a small number have been granted. Germany decriminalised cannabis possession in 2024 but has not moved on psilocybin beyond the research setting. The UK maintains a Class A prohibition, more restrictive than Australia; and clinical research requires a Schedule 1 Home Office licence, which is administratively burdensome enough that researchers describe it as a genuine obstacle to trial conduct.

The European Medicines Agency has not approved any psychedelic compound. EU-wide regulatory harmonisation on this front is a long way off, and individual member states are at very different points in even the research conversation.

What drives the differences?

The short version is: scheduling history, political context, and the strength of domestic clinical advocacy. Australia's move was partly driven by sustained lobbying from mental health researchers, the existence of well-run local Phase II trial data, and a TGA review process that, while cautious, is structured to respond to evidence submissions in a formal way.

The US federal impasse is a product of the Schedule I classification's political stickiness, any rescheduling requires DEA and FDA coordination, and there are genuine scientific debates about whether the evidence base justifies moving away from Schedule I at a federal level. Breakthrough Therapy designation accelerates research but doesn't predetermine scheduling outcomes.

In my view, the Australian model is more coherent than most, but "more coherent" doesn't mean "accessible in practice." The number of approved Authorised Prescribers remains low, geographic access is uneven, and the cost of treatment under this framework is significant. The regulatory architecture is there; the actual delivery is a different question.

The research side: what studies report

Separate from access frameworks, the academic literature on psilocybin's mechanism has expanded considerably. Psilocybin is a prodrug; it's metabolised to psilocin, which acts primarily as a 5-HT2A receptor agonist; meaning it binds to serotonin receptors, particularly in the prefrontal cortex. The pharmacokinetics are reasonably well characterised in healthy-volunteer studies.

Published clinical trials, including those from Johns Hopkins University and Imperial College London, have examined psilocybin in controlled settings with screening protocols, preparation sessions, trained facilitators, and follow-up. These studies are conducted under strict regulatory approvals and report dose ranges as part of their methodology. Reporting what studies used is description of research, not a dosing protocol. The distinction matters. Nobody should interpret that information as instruction for unsupervised use; particularly given the well-documented risks of acute psychological distress, persisting perception disorder, and contraindications in people with personal or family history of psychosis.

The ADF (Australian Drug Foundation) maintains up-to-date information on risk profiles. It is worth reading before drawing conclusions from headlines about trial outcomes.

Where things are heading

The global picture suggests incremental, jurisdiction-by-jurisdiction movement rather than any coordinated international shift. The UN's 1971 Convention on Psychotropic Substances, which underpins scheduling in most signatory countries, has not been revised to accommodate emerging research. Countries working within that framework are doing so through domestic scheduling adjustments and research exemptions, not by stepping outside the international treaty architecture.

Australia's 2023 decision is genuinely significant in that context, it's one of the first national-level, prescriber-pathway adjustments made by a country working within standard scheduling conventions. Whether other countries follow, and how quickly, depends on trial data, political will, and how the early Australian clinical experience is documented and communicated.

That documentation is still being written. The Authorised Prescriber pathway has been active for less than two years. What the clinical record looks like at the five-year mark will matter a great deal for what happens elsewhere.

Sources

• TGA approves use of MDMA and psilocybin by Authorised Prescribers, Therapeutic Goods Administration (TGA)
• Magic mushrooms: drug facts; Australian Drug Foundation (ADF)
• Psilocybin-assisted therapy: a review of a new paradigm for the treatment of psychiatric disorders, National Center for Biotechnology Information (NCBI/NIH)
• The global state of psychedelic policy reform, NCBI/NIH

, Daniel Okoro, Psychedelic science & law writer